î
îž
āļĨāđāļāļāļāļīāļ
î
Ascendis Pharma A/S
ASND221.408USD
+0.508+0.23%
āđāļ§āļĨāļēāļāļģāļāļēāļĢāļāļĨāļēāļÂ ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
5.08BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
āļāļēāļāļāļļāļP/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Ascendis Pharma A/S āļāļĢāļīāļĐāļąāļ
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
āļāđāļāļĄāļđāļĨ Ascendis Pharma A/S
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļASND
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAscendis Pharma A/S
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJan 28, 2015
āļāļĩāļāļĩāđāļMoller Mikkelsen (Jan)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒDepository Receipt
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJan 28
āļāļĩāđāļāļĒāļđāđTuborg Boulevard 12
āđāļĄāļ·āļāļHELLERUP
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻDenmark
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ2900
āđāļāļĢāļĻāļąāļāļāđ4570222244
āđāļ§āđāļāđāļāļāđhttps://ascendispharma.dk/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļASND
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJan 28, 2015
āļāļĩāļāļĩāđāļMoller Mikkelsen (Jan)
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ Ascendis Pharma A/S
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Mr. Jan Moller Mikkelsen
Mr. Jan Moller Mikkelsen
President, Chief Executive Officer, Executive Director, Member of the Executive Board
President, Chief Executive Officer, Executive Director, Member of the Executive Board
--
--
Ms. Lotte Soenderbjerg
Ms. Lotte Soenderbjerg
Executive Vice President, Chief Administrative Officer, Member of the Executive Board
Executive Vice President, Chief Administrative Officer, Member of the Executive Board
--
--
Dr. Kennett Sprogoee, Ph.D.
Dr. Kennett Sprogoee, Ph.D.
Executive Vice President, Head of Innovation and Research
Executive Vice President, Head of Innovation and Research
--
--
Mr. Scott T. Smith
Mr. Scott T. Smith
Chief Financial Officer, Executive Vice President, Member of the Executive Board
Chief Financial Officer, Executive Vice President, Member of the Executive Board
--
--
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Mr. Jan Moller Mikkelsen
Mr. Jan Moller Mikkelsen
President, Chief Executive Officer, Executive Director, Member of the Executive Board
President, Chief Executive Officer, Executive Director, Member of the Executive Board
--
--
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 6 āļĄ.āļ.
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 6 āļĄ.āļ.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Commercial sale of products
193.79M
90.71%
Milestones
12.92M
6.05%
Rendering of services
6.13M
2.87%
License
788.00K
0.37%
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
North America
161.13M
75.42%
Europe
29.28M
13.71%
Rest of world
19.12M
8.95%
Denmark
4.10M
1.92%
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Commercial sale of products
193.79M
90.71%
Milestones
12.92M
6.05%
Rendering of services
6.13M
2.87%
License
788.00K
0.37%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 18 āļĄāļĩ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 18 āļĄāļĩ.āļ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
RA Capital Management, LP
16.59%
Westfield Capital Management Company, L.P.
8.37%
Avoro Capital Advisors LLC
8.25%
Janus Henderson Investors
6.55%
Fidelity Management & Research Company LLC
6.13%
āļāļ·āđāļ āđ
54.11%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
RA Capital Management, LP
16.59%
Westfield Capital Management Company, L.P.
8.37%
Avoro Capital Advisors LLC
8.25%
Janus Henderson Investors
6.55%
Fidelity Management & Research Company LLC
6.13%
āļāļ·āđāļ āđ
54.11%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Investment Advisor/Hedge Fund
41.62%
Investment Advisor
36.71%
Venture Capital
16.81%
Hedge Fund
6.23%
Research Firm
3.00%
Private Equity
2.24%
Individual Investor
0.82%
Pension Fund
0.45%
Sovereign Wealth Fund
0.38%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļĢāđāļāļĩāđ 8 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļĢāđāļāļĩāđ 8 āļ.āļ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2025Q4
523
68.62M
116.45%
+3.30K
2025Q3
540
68.73M
112.39%
+4.25M
2025Q2
515
64.43M
118.51%
-2.60M
2025Q1
495
67.05M
117.13%
-3.67M
2024Q4
471
65.26M
121.58%
+1.14M
2024Q3
461
64.02M
116.74%
+1.57M
2024Q2
446
62.31M
123.50%
-4.72K
2024Q1
440
62.32M
122.74%
-9.15M
2023Q4
415
61.74M
123.84%
-59.49K
2023Q3
401
61.90M
129.48%
-512.07K
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļ
îāļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
RA Capital Management, LP
10.28M
16.59%
--
--
Sep 30, 2025
Westfield Capital Management Company, L.P.
5.26M
8.49%
-191.49K
-3.51%
Sep 30, 2025
Avoro Capital Advisors LLC
5.11M
8.24%
+130.00K
+2.61%
Sep 30, 2025
Janus Henderson Investors
4.32M
6.98%
-104.73K
-2.37%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.12M
6.65%
-59.30K
-1.42%
Sep 30, 2025
Artisan Partners Limited Partnership
3.72M
6%
-269.54K
-6.75%
Sep 30, 2025
Capital International Investors
3.06M
4.94%
+13.69K
+0.45%
Sep 30, 2025
MFS Investment Management
1.88M
3.03%
-18.93K
-1.00%
Sep 30, 2025
Wellington Management Company, LLP
1.80M
2.9%
+880.84K
+95.94%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
2.67M
4.3%
-916.93K
-25.59%
Sep 30, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 6 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 6 āļ.āļ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
Harbor Health Care ETF
17.71%
American Century Focused Dynamic Growth ETF
2.8%
AdvisorShares Dorsey Wright ADR ETF
2.62%
Virtus LifeSci Biotech Products ETF
1.89%
Tema Heart & Health ETF
1.45%
ProShares Ultra Nasdaq Biotechnology
1.2%
Invesco Nasdaq Biotechnology ETF
1.19%
First Trust Innovation Leaders ETF
1.18%
Putnam Sustainable Future ETF
1.11%
Main Thematic Innovation ETF
1.07%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Harbor Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ17.71%
American Century Focused Dynamic Growth ETF
āļŠāļąāļāļŠāđāļ§āļ2.8%
AdvisorShares Dorsey Wright ADR ETF
āļŠāļąāļāļŠāđāļ§āļ2.62%
Virtus LifeSci Biotech Products ETF
āļŠāļąāļāļŠāđāļ§āļ1.89%
Tema Heart & Health ETF
āļŠāļąāļāļŠāđāļ§āļ1.45%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ1.2%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ1.19%
First Trust Innovation Leaders ETF
āļŠāļąāļāļŠāđāļ§āļ1.18%
Putnam Sustainable Future ETF
āļŠāļąāļāļŠāđāļ§āļ1.11%
Main Thematic Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ1.07%
āđāļāļīāļāļāļąāļāļāļĨ
îāļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļ
îāļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
